Home >  Diabetes and Endocrinology MDTV >  Diabetes & Endocrinology Shorts >  Study finds Semaglutide's...

Study finds Semaglutide's effects on long-term weight loss in individuals with obesity

By - Anshika Mishra
Published On 2024-05-15 03:00 GMT   |   Update On 2024-05-15 08:43 GMT
Advertisement
Two studies presented at the European Congress on Obesity investigated the long-term effects of semaglutide on weight loss and explored the relationship between cardiovascular benefits and initial weight or extent of weight loss.
Semaglutide, a GLP-1 medication typically prescribed for adults with type 2 diabetes, is also approved for weight management in individuals with obesity or overweight who have at least one comorbidity. This medication class mimics the actions of the body's natural incretin hormones, aiding in post-meal blood sugar regulation. By modulating these hormone levels, semaglutide can induce a feeling of fullness, thereby reducing daily calorie consumption.
In the SELECT trial spanning from October 2018 to June 2023, 17,604 adults aged 45 or older from 41 countries were given semaglutide (2.4mg) or placebo for an average of 40 months. They were overweight or obese but no diabetes and a history of cardiovascular events.
The findings are as follows:
1. Semaglutide users saw a 20% lower risk of heart attack, stroke, or cardiovascular death and lost an average of 9.4% body weight.
Advertisement
2. In the semaglutide group, weight loss persisted up to week 65 and was maintained for four years, with participants achieving an average body weight reduction of 10.2% and a waistline decrease of 7.7cm, compared to 1.5% and 1.3cm respectively in the placebo group.
3. The semaglutide group experienced a significant 6.9% reduction in average waist circumference-to-height ratio, compared to 1% in the placebo group. After two years, over half (52%) of semaglutide-treated participants shifted to a lower BMI category, compared to 16% of those receiving placebo.
4. Semaglutide treatment provided cardiovascular benefits regardless of initial weight or the extent of weight loss. This implies that even individuals with mild obesity or modest weight loss may experience improved cardiovascular outcomes with semaglutide therapy.
“Our findings show that the magnitude of this treatment effect with semaglutide is independent of the amount of weight lost, suggesting that the drug has other actions which lower cardiovascular risk beyond reducing unhealthy body fat. These alternative mechanisms may include positive impacts on blood sugar, blood pressure, or inflammation, as well as direct effects on the heart muscle and blood vessels, or a combination of one or more of these,” said Professor John Deanfield from University College London, UK.
Reference: Ryan, D.H., Lingvay, I., Deanfield, J. et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-02996-7
Full View
Tags:    
Article Source : European Congress on Obesity

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Anshika Mishra

Anshika Mishra is a dedicated scholar pursuing a Masters in Biotechnology, driven by a profound passion for exploring the intersection of science and healthcare. Having embarked on this academic journey with a passion to make meaningful contributions to the medical field, Anshika joined Medical Dialogues in 2023 to further delve into the realms of healthcare journalism.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

The Prediabetes Show - Episode 1: Reversing Prediabetes - Myth or Fact?

This Brain Hormone May Control Blood Sugar Without Insulin: Study Suggests

Indian Study Shows Type 2 Diabetes Remission May Be Possible without Surgery or Extreme Diets

Shedding Weight, Losing Muscle: Study Links GLP-1 Drugs to Reduced Muscle Mass

Non-Invasive Saliva Test May Detect Early Signs of Diabetes and Obesity: Study Finds

Low Blood Sugar Before Pregnancy May Raise Risk of Preterm Birth, Low Birth Weight: Study Finds

Even Few Workouts a Week Could Lower Death Risk for People with Diabetes: Study Suggests

Yoga May Reduce the Risk of Developing Diabetes by 40 Percent: Study Shows